Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Status:
Completed

Trial end date:
2019-04-26

Target enrollment:

Participant gender:

This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.

Phase 4

Bayer

Regeneron Pharmaceuticals

Aflibercept